Apollomics announces report of activity of vebreltinib in glioblastoma multiforme (gbm) with ptprz-met fusion

Foster city, calif., oct. 26, 2023 (globe newswire) -- apollomics inc. (nasdaq: aplm) (the “company”), today announced a report by the veneto institute of oncology on the efficacy response of a patient treated with vebreltinib for gbm with ptprz-met fusion, at the european society of medical oncology congress (esmo) 2023, held in madrid, spain from october 20-24, 2023.
APLM Ratings Summary
APLM Quant Ranking